<DOC>
	<DOCNO>NCT01721525</DOCNO>
	<brief_summary>This study seek develop new induction chemotherapy regimen combination two pill drug take mouth two drug give vein . This phase I study , mean primary goal establish recommend dose investigational drug add chemotherapy . The researcher wish evaluate effect , good bad , investigational drug .</brief_summary>
	<brief_title>Induction Chemotherapy With Afatinib , Ribavirin , Weekly Carboplatin/Paclitaxel Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer ( OPSCC )</brief_title>
	<detailed_description />
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Squamous Cell</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Department Pathology MSKCC confirmation diagnosis oropharynx squamous cell cancer , stage IVA/IVB , HPV associate . Evidence HPV p16 immunohistochemistry and/or HPV situ hybridization positive test result tumor tissue , either MSKCC CLIAapproved lab . Age ≥ 18 year age Karnofsky Performance Status ≥ 80 Adequate organ function , follow : Adequate bone marrow reserve : absolute neutrophil count ( ANC ) ≥ 1.5 X 109/L , platelet ≥ 160 X 109/L , hemoglobin ≥ 12 g/dL Hepatic : total bilirubin within normal limit ( ≤ 1.0 mg/dL ) ; alkaline phosphatase ( AP ) , aspartate transaminase ( AST ) alanine transaminase ( ALT ) ≤ 1.5 X ULN ( upper limit normal ) Renal : Serum creatinine ≤ 1.3 mg/dL . Patients serum creatinine &gt; 1.3 mg/dL may eligible creatinine clearance ( CrCl ) ≥ 55 mL/min base standard Cockroft Gault formula . Patients childbearing potential must negative serum pregnancy test within 14 day treatment . Patients must agree use reliable method birth control 6 month follow last dose study drug . Ability swallow oral medication . Expansion Cohort : At least one unstained slide pretreatment diagnostic biopsy fine needle aspirate must available correlative immunohistochemistry study . Prior chemotherapy radiation tonsillar base tongue squamous cell cancer History hemolytic anemia thalassemia Active infection serious underlie medical condition would impair patient 's ability receive protocol treatment . Current therapeutic anticoagulation Coumadin ( warfarin ) Current prior treatment ribavirin Known active Hepatitis B C Any prior document history transient ischemic attack ( TIA ) cerebrovascular accident ( CVA ) New York Heart Association ( NYHA ) Grade II great congestive heart failure Clinically significant peripheral vascular disease Inability discontinue follow potent Pgp inhibitor ( cyclosporine , erythromycin , ketoconazole , itraconazole , quinidine , phenobarbital salt quinidine , ritonavir , valspodar , verapamil ) inducer ( St John 's wort , rifampicin ) . Known preexist interstitial lung disease . Presence poorly control gastrointestinal disorder could affect absorption trial drug ( e.g . Crohn 's disease , ulcerative colitis , malabsorption , CTC grade ≥2 diarrhea etiology ) base treat physician assessment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>BIBW2992 ( AFATINIB )</keyword>
	<keyword>CARBOPLATIN</keyword>
	<keyword>RIBAVIRIN-ICN ( VIRAZOLE )</keyword>
	<keyword>TAXOL ( PACLITAXEL )</keyword>
	<keyword>OROPHARYNX</keyword>
	<keyword>HPV associate</keyword>
	<keyword>12-150</keyword>
</DOC>